A PHASE 1, OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY, AND PRELIMINARY CLINICAL ACTIVITY OF ALLOGENEIC INVARIANT NATURAL KILLER T (INKT) CELLS (AGENT-797) AS A SINGLE AGENT AND IN COMBINATION WITH APPROVED IMMUNE CHECKPOINT INHIBITORS IN SUBJECTS WITH RELAPSED/REFRACTORY SOLID TUMORS

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Breelyn Wilky,  MD

Breelyn Wilky, MD

Study ID

Protocol Number: 22-0878

More information available at ClinicalTrials.gov: NCT05108623

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers